Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769134 | 0.82 | KMT2A (0.51) | PIN1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL29484101 | 0.82 | KMT2A (0.51) | PIN1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL651410 | 0.82 | HTT (0.51) | LMNAPIN1ALDH1A1HTTIDO1 | |
| SCHEMBL2529181 | 0.79 | LMNA (0.51) | LMNAALDH1A1HTTCYP1A2MEN1 | |
| SCHEMBL10708816 | 0.79 | LMNA (0.43) | LMNAPIN1ALDH1A1HTTXBP1 | |
| SCHEMBL2115724 | 0.78 | ALDH1A1 (0.51) | LMNAPIN1ALDH1A1HTTXBP1 | |
| SCHEMBL2607721 | 0.78 | ALDH1A1 (0.45) | PIN1ALDH1A1HTTXBP1IDO1 | |
| SCHEMBL31262315 | 0.77 | HTT (0.49) | PIN1ALDH1A1HTTXBP1MEN1 | |
| SCHEMBL2448483 | 0.77 | HTT (0.49) | PIN1ALDH1A1HTTXBP1MEN1 | |
| SCHEMBL10816187 | 0.77 | HTT (0.47) | PIN1ALDH1A1HTTIDO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250238-A1 | SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT | SANGALLI MARIA EDVIGE | 2011-10-13 | — | — | US | disclosed |
| EP-1965828-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | Nastech Pharmaceutical Company Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007146448-A1 | PHARMACEUTICAL FORMULATIONS OF GLP-1 DERIVATIVES | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007065156-A2 | PHARMACEUTICAL FORMULATION FOR INCREASED EPITHELIAL PERMEABILITY OF GLUCOSE-REGULATING PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-07 | — | — | WO | disclosed |